Vorinostat

Vorinostat is a hydroxamic acid compound that inhibits histone deacetylases, enzymes that remove acetyl groups from histones and other proteins ^[1]. It emerged from research into how such compounds can push cancer cells to differentiate or die, and it became the first drug of its kind to reach approval ^[1]. It is marketed under a brand name and given as an oral capsule ^[1].

The drug received United States approval in 2006 for the treatment of the skin manifestations of cutaneous T-cell lymphoma, a group of non-Hodgkin lymphomas that appear in the skin, in patients whose disease has progressed, persisted, or recurred after other systemic therapies ^[1][2]. In the trials that supported approval it produced meaningful responses in a portion of patients with advanced, treatment-resistant disease, including those with the Sezary syndrome variant ^[1]. Histone deacetylase inhibitors as a class have proven particularly active against T-cell lymphomas ^[2].

Beyond its approved indication, vorinostat has been investigated in a range of other cancers, both alone and in combination, and in a later randomized phase 3 trial it served as the comparator against a newer antibody therapy in previously treated cutaneous T-cell lymphoma ^[3]. It has also been studied experimentally outside oncology, including efforts to reverse the latency of HIV, reflecting the broad influence of histone deacetylase inhibition on gene expression ^[1].

The common side effects of vorinostat include fatigue, gastrointestinal symptoms such as nausea and diarrhea, and reductions in blood cell counts, notably a fall in platelets; a more serious concern is an increased tendency to blood clots ^[1]. Patients on treatment are monitored for these effects, and the drug can also affect blood glucose and the heart's electrical conduction ^[1].

Vorinostat is a prescription-only medicine and was granted orphan drug status, a designation for treatments of rare diseases ^[1]. It is used under specialist supervision in oncology, and its place in therapy has continued to evolve as newer agents for cutaneous T-cell lymphoma have become available ^[2][3].

Vorinostat is a potent prescription chemotherapy drug, not a supplement, and its side effects reflect that: fatigue, nausea, diarrhea, and importantly low platelet counts and other blood-count changes, plus risks of blood clots and QT prolongation. It requires medical monitoring and is inappropriate for casual nootropic self-use. The pro-cognitive and neuroprotective data are almost entirely from animal models at low doses, and extrapolating to healthy human use is not justified given the toxicity. Not medical advice.

Vorinostat has a documented interaction with warfarin; co-administration with other histone deacetylase inhibitors poses a similar risk. In animal models, vorinostat induces CYP2C19 and inhibits CYP1A2, CYP2B6, and CYP2D6, suggesting potential for altering metabolism of drugs dependent on these enzymes, though clinical significance remains unclear ^[22]. Most other medications have not been systematically studied with vorinostat in humans.

Checking a whole stack? Run it through interactions + stacks.